Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (111-120 of 282) with videos related to

Pageof 29
Sort By:
The Journal of Antimicrobial Chemotherapy|February 20, 2019
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteersEmilie R Elliot, Maddalena Cerrone, Elizabeth Challenger, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledgeEmilie R Elliot, Alieu Amara, Nicole Pagani, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjectsBorja Mora-Peris, Adam Croucher, Laura J Else, et al.
The Journal of Antimicrobial Chemotherapy|October 2, 2018
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteersEmilie R Elliot, Maddalena Cerrone, Elizabeth Challenger, et al.
NPJ Systems Biology and Applications|May 6, 2024
DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapyThao Pham, Mohamed Ghafoor, Sandra Grañana-Castillo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Clinical ManifestationsAnna Jane Dreyer, Celine Le Roux, Kevin G F Thomas, et al.
Wellcome Open Research|August 30, 2022
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometryAdeniyi Olagunju, Jacinta Nwogu, Oluwasegun Eniayewu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional StudyToyosi Solanke, Festus Kamau, Tonya Esterhuizen, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
Pageof 29

Showing results (111-120 of 282) with videos related to

Sort By:
Pageof 29
The Journal of Antimicrobial Chemotherapy|February 20, 2019
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteersEmilie R Elliot, Maddalena Cerrone, Elizabeth Challenger, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledgeEmilie R Elliot, Alieu Amara, Nicole Pagani, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 2013
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjectsBorja Mora-Peris, Adam Croucher, Laura J Else, et al.
The Journal of Antimicrobial Chemotherapy|October 2, 2018
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteersEmilie R Elliot, Maddalena Cerrone, Elizabeth Challenger, et al.
NPJ Systems Biology and Applications|May 6, 2024
DeepARV: ensemble deep learning to predict drug-drug interaction of clinical relevance with antiretroviral therapyThao Pham, Mohamed Ghafoor, Sandra Grañana-Castillo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 24, 2025
Clinical ManifestationsAnna Jane Dreyer, Celine Le Roux, Kevin G F Thomas, et al.
Wellcome Open Research|August 30, 2022
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometryAdeniyi Olagunju, Jacinta Nwogu, Oluwasegun Eniayewu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2022
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional StudyToyosi Solanke, Festus Kamau, Tonya Esterhuizen, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
Pageof 29